D. E. Shaw & Co., Inc. Centessa Pharmaceuticals PLC Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 48,078 shares of CNTA stock, worth $825,018. This represents 0.0% of its overall portfolio holdings.
Number of Shares
48,078Holding current value
$825,018% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding CNTA
# of Institutions
108Shares Held
118MCall Options Held
5.9KPut Options Held
53K-
Medicxi Ventures Management (Jersey) LTD20MShares$343 Million66.33% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$171 Million100.0% of portfolio
-
General Atlantic LLC New York, NY9.68MShares$166 Million4.42% of portfolio
-
Perceptive Advisors LLC New York, NY6.28MShares$108 Million2.62% of portfolio
-
First Light Asset Management, LLC Edina, MN5.94MShares$102 Million8.27% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $1.62B
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...